본문 바로가기

Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
BRITISH JOURNAL OF HAEMATOLOGY189(2) · pp.303 · 2020
피인용
Web of Science 21Scopus 23
FWCI (Scopus)
0
JCR IF
JCR 2019 5.518
ISSN
0007-1048

저자

  1. Do, Young Rok제1저자Dongsan Medical Center, Keimyung University, Daegu, South Korea
  2. Kwak, Jae-YongChonbuk National University Medical School & Hospital, Jeonju, South Korea
  3. Kim, Jeong A.St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea
  4. Kim, Hyeoung JoonChonnam National University, Hwasun Hospital, Hwasun, South Korea
  5. 정주섭Pusan National University Hospital, Busan, South Korea
  6. 신호진Pusan National University Hospital, Busan, South Korea
  7. Kim, Sung-HyunDong-A University Medical Center, Busan, South Korea
  8. Bunworasate, UdomsakKing Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
  9. Choi, Chul WonKorea University, Guro Hospital, Seoul, South Korea
  10. Zang, Dae YoungHallym University Sacred Heart Hospital, Anyang, South Korea
  11. Oh, Suk JoongKangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
  12. Jootar, SaengsureeFaculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  13. Reksodiputro, Ary HarryantoRumah Sakit Dr, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  14. Lee, Won SikInje University Busan Paik Hospital, Busan, South Korea
  15. Mun, Yeung-ChulEwha Womans University College of Medicine, Seoul, South Korea
  16. Kong, Jee HyunWonju Severance Christian Hospital, Wonju, South Korea
  17. Caguioa, Priscilla B.St. Luke’s Medical Center, Quezon, Philippines
  18. Kim, HawkGachon University Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
  19. Park, JinnyGachon University Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
  20. Kim, Dong-Wook교신저자Seoul St. Mary's Hematology Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea

초록

In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With >= 48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 <= 10% at three months, MMR and molecular response 4 center dot 5 (MR4 center dot 5) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0 center dot 0197) or 400 mg (5%; P = 0 center dot 0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable.

키워드

chronic myeloid leukaemiaimatinibnewly diagnosedlong-term dataradotinibDASATINIBTRIALDISCONTINUATIONINHIBITORNILOTINIBEFFICACYTHERAPYSAFETY

식별자

Scopus EID
2-s2.0-85078900629
WoS UID
000510537100001